Ta Hsung Tung

Array ( [id] => 10791575 [patent_doc_number] => 20160137731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-19 [patent_title] => 'HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 14/822651 [patent_app_country] => US [patent_app_date] => 2015-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 41745 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14822651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11805193 [patent_doc_number] => 09546206 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-17 [patent_title] => 'High affinity PD-1 agents and methods of use' [patent_app_type] => utility [patent_app_number] => 14/821589 [patent_app_country] => US [patent_app_date] => 2015-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 52 [patent_no_of_words] => 45239 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14821589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693981 [patent_doc_number] => 20160040127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'USE OF LIGANDS FOR THE PROGRAMMED CELL DEATH RECEPTOR CONJUGATED TO SOLID SUPPORTS FOR THE EXPANSION OF HUMAN REGULATORY T CELLS' [patent_app_type] => utility [patent_app_number] => 14/820795 [patent_app_country] => US [patent_app_date] => 2015-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 8435 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14820795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17251168 [patent_doc_number] => 11186640 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => Method for the identification of immunotherapy-drug combinations using a network approach [patent_app_type] => utility [patent_app_number] => 15/500498 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 18 [patent_no_of_words] => 12819 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15500498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10670894 [patent_doc_number] => 20160017039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'USE OF AN ACTIVE SUBSTANCE BINDING TO CD28 FOR PRODUCING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF B-CLL' [patent_app_type] => utility [patent_app_number] => 14/813881 [patent_app_country] => US [patent_app_date] => 2015-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 5461 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14813881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10506177 [patent_doc_number] => 09234043 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2016-01-12 [patent_title] => 'Anti-human OX40L antibodies' [patent_app_type] => utility [patent_app_number] => 14/811163 [patent_app_country] => US [patent_app_date] => 2015-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 7 [patent_no_of_words] => 67649 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14811163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10714195 [patent_doc_number] => 20160060343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'CANCER TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/805854 [patent_app_country] => US [patent_app_date] => 2015-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11575 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14805854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12099229 [patent_doc_number] => 09856318 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-02 [patent_title] => 'Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS' [patent_app_type] => utility [patent_app_number] => 14/797894 [patent_app_country] => US [patent_app_date] => 2015-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 56 [patent_no_of_words] => 21335 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14797894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10548524 [patent_doc_number] => 09273135 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-01 [patent_title] => 'Human monoclonal antibodies to programmed death ligand 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/796956 [patent_app_country] => US [patent_app_date] => 2015-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 65 [patent_no_of_words] => 44079 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 465 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14796956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12212142 [patent_doc_number] => 09908937 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-06 [patent_title] => 'Compositions monovalent for CD28 binding and methods of use' [patent_app_type] => utility [patent_app_number] => 14/740709 [patent_app_country] => US [patent_app_date] => 2015-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 62338 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14740709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106297 [patent_doc_number] => 09862767 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Therapeutic methods using anti-CD200 antibodies' [patent_app_type] => utility [patent_app_number] => 14/739862 [patent_app_country] => US [patent_app_date] => 2015-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 33503 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 446 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14739862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12945700 [patent_doc_number] => 09834606 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-05 [patent_title] => Anti-PD1 antibodies and their use as therapeutics and diagnostics [patent_app_type] => utility [patent_app_number] => 14/736966 [patent_app_country] => US [patent_app_date] => 2015-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 15943 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14736966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14609765 [patent_doc_number] => 10357561 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-23 [patent_title] => BTNL9 proteins, nucleic acids, and antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 14/704794 [patent_app_country] => US [patent_app_date] => 2015-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 24264 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14704794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10103880 [patent_doc_number] => 09139653 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-09-22 [patent_title] => 'Anti-human OX40L antibodies and methods of treatment' [patent_app_type] => utility [patent_app_number] => 14/700896 [patent_app_country] => US [patent_app_date] => 2015-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 7 [patent_no_of_words] => 69575 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14700896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12086842 [patent_doc_number] => 09840562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-12 [patent_title] => 'Binding molecules to the human OX40 receptor' [patent_app_type] => utility [patent_app_number] => 14/692948 [patent_app_country] => US [patent_app_date] => 2015-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 16 [patent_no_of_words] => 23087 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14692948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10430268 [patent_doc_number] => 20150315281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/684550 [patent_app_country] => US [patent_app_date] => 2015-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 26587 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14684550 [rel_patent_id] =>[rel_patent_doc_number] =>)